Lemtrada (alemtuzumab) - Risk Of Autoimmune Hepatitis, Haemophagocytic Lymphohistiocytosis, And Associated Serious Cardiovascular Reactions

LEMTRADA (alemtuzumab), a medication distributed across Canada, is being recalled due to risks of autoimmune hepatitis, haemophagocytic lymphohistiocytosis, and serious cardiovascular reactions. The drug is used to treat certain conditions, and these serious side effects have been identified as a safety concern. People currently taking this medication should consult their healthcare provider about this recall.

Reason

Product safety

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2019-10-15

Status

Ongoing

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/e5ea7cf0-9257-41fa-b6f3-7c5c08a816a2